Ocular Mysathenia Gravis Generalization — MYASTEN

Ocular Myasthenia Gravis Clinical Trial

Official title:
Use of Nomogram for Predictions of Ocular Mysathenia Gravis Generalization

Status Completed

Clinical Trial Summary

Secondary ocular myasthenia gravis (OMG) generalization represents a pejorative evolution and no validated generalization prevention strategy exists. The aim of this observational study was to determine the percentage of patients with OMG generalization and identify factors predictive of that pejorative evolution. Data from patients with OMG registered in the Fondation Hospital A. de Rothschild database between January 1990 and January 2017 were collected. Among the 183 patients registered in this database, 151 patients with available informations were analyzed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04667650
Study type	Observational
Source	Fondation Ophtalmologique Adolphe de Rothschild
Contact
Status	Completed
Phase
Start date	January 2017
Completion date	January 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04182984` - TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
Not yet recruiting	`NCT06342544` - Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.	Phase 3
Completed	`NCT05045248` - Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis	Phase 2
Recruiting	`NCT05091177` - Study on Correlation Between Cytomegalovirus and Ocular Myasthenia Gravis
Terminated	`NCT00995722` - Efficacy of Prednisone In the Treatment of Ocular Myasthenia	Phase 3